Skip to search formSkip to main contentSkip to account menu

HDAC-42

Known as: AR-42, HDAC Inhibitor AR-42, OSU-HDAC42 
An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, AR… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

Phenylbutyrates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Synthesis, cytotoxic activity, and mode of action of new Santacruzamate A analogs
Breast and ovarian cancer are the most common cancers in women. Available cancer treatments, in general, have limited efficacy… 
2018
2018
Investigation of epigenetic inhibitors as anti-plasmodial drug leads
Malaria, caused by Plasmodium parasite species, remains one of the most devastating infectious diseases and is a major public… 
2016
2016
On concentration of Ar-42 in liquid argon
2016
2016
On concentration of Ar-42 in the Earth's atmosphere
Data from the DBA liquid argon ionization chamber experiment have been used to obtain an estimate on the concentration of 42Ar in… 
2014
2014
GAPLINC and gastric cancer
Written by Orli Bahcall, Brooke LaFlamme, Emily Niemitz & Kyle Vogan model of Kmt2d haploinsufficiency and test the potential… 
2014
2014
Kabuki syndrome and HDAC inhibitors
model of Kmt2d haploinsufficiency and test the potential effective-ness of histone deacetylase inhibitor (HDACi) therapy ( Sci… 
2014
2014
Flies point to human disease genes
model of Kmt2d haploinsufficiency and test the potential effective-ness of histone deacetylase inhibitor (HDACi) therapy ( Sci… 
2014
2014
FANCM and breast cancer risk
model of Kmt2d haploinsufficiency and test the potential effective-ness of histone deacetylase inhibitor (HDACi) therapy ( Sci… 
2013
2013
Abstract 4392: Targeting HADC-2: Chemopreventive effect of OSU-HDAC42 on rat colon carcinogenesis and APCmin/+ Mice intestinal tumorigenesis.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Epigenetic modulators particularly histone… 
2006
2006
The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.
Inhibitors of histone deacetylase (HDAC) have generated major interest for the treatment of multiple cancers including B-cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)